Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · NOVYRA PHARMACHEM LIMITED · 12 September 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
NOVYRA PHARMACHEM LIMITED BSE: 519353
Fast Moving Consumer Goods › Fast Moving Consumer Goods › Agricultural Food & other Products › Tea & Coffee
NOVYRA PHARMACHEM LIMITED
StateQ1 FY27 filed
Last close · 9 Sept 2026₹10.14
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA1.2 · 10.79 · —
NOVYRA PHARMACHEM LIMITED is a Agricultural Food & other Products company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
₹ crore · consolidated
FY22
FY23
FY24
FY25
FY26
Revenue
0
0
0
0
0
EBITDA (ex other income)
(0)
0
(0)
(0)
(5)
margin %
(10.3)
30.1
—
—
(5180.1)
Owners' profit
0
0
(0)
(0)
(5)
EPS, as reported (₹)
0.00
0.02
(0.03)
0.10
8.49
ROE % · ROCE %
0.1 · 0.1
0.2 · 0.5
(2.7) · (2.6)
(1.1) · (1.1)
(907.6) · (907.6)
Debt / equity (x)
0.00
0.00
0.00
0.03
0.00
Cash from operations
(1)
0
(0)
(0)
(4)
Capex
0
0
0
0
0
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · NOVYRA PHARMACHEM LIMITED · 12 September 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
₹ crore
Q2 FY25
Q3 FY25
Q4 FY25
Q1 FY26
Q2 FY26
Q3 FY26
Q4 FY26
Q1 FY27
Revenue
0
0
0
0
0
0
0
2
Profit before tax
(0)
(0)
(0)
(0)
0
(0)
(5)
(0)
Net profit
(0)
(0)
(0)
(0)
0
(0)
(5)
(0)
EPS (₹)
0.00
(0.02)
0.08
0.03
0.00
0.02
8.43
0.03
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Segment revenue, FY26
Segment
Revenue, ₹ crore
Share %
Segment - Pharma
0
9.6
Segment - Real Estate
0
4.8
Segment - Tea Estate
0
85.6
Total, before eliminations
0
100.0
Source: the filed segment block, four quarters summed.
Exhibit 4: Peers — basic industry group, by market cap
Company
M.cap ₹ cr
P/E
P/B
EV/EBITDA
ROE %
ROCE %
Rev CAGR 5y %
EBITDA m. %
TATA CONSUMER PRODUCT LTD
98,069
60.0
4.23
33.1
6.7
7.8
11.8
14.9
Dossier · NOVYRA PHARMACHEM LIMITED · 12 September 2026Page 3 of 3
Exhibit 6: Filings of the last 90 days, with the measured price reaction
Date · filing
Category
Importance
1-day %
5-day %
22 Aug 2026 · Name change to Novyra Pharmachem, pivot into pharma and contract services
business updates
high
—
—
11 Aug 2026 · Board meeting on Aug 14 to consider Q1 FY27 results
results
low
—
—
4 Aug 2026 · Change of website address to novyrapharmachemltd.com
general
minimal
—
—
13 Jul 2026 · RTA compliance certificate under SEBI Reg 74(5) for Apr-Jun 2026
26 Jun 2026 · AGM 2026: All 5 resolutions passed, capital reduction approved
board shareholder meetings
low
—
—
25 Jun 2026 · 39th AGM held; Capital Reduction and MD appointment approved
board shareholder meetings
low
—
—
5 Jun 2026 · Annual Report 2025-2026
compliance
low
—
—
1 Jun 2026 · Annual Report 2025-2026
results
high
—
—
1 Jun 2026 · AGM Notice
board shareholder meetings
low
—
—
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
Where a broker report shows
This document shows
Why
A rating (BUY / ADD / REDUCE / SELL)
A state: the latest filed quarter and the measured reactions
an event is a fact; a rating is an opinion that requires SEBI RA registration
A target price and upside
CCL PRODUCTS (I) LTD
14,354
33.1
6.12
20.8
16.6
16.2
29.1
16.4
VINTAGE COFFEE N BVRGS L
2,549
32.3
4.48
24.1
12.7
14.0
—
20.6
ANDREW YULE & CO. LTD.
1,275
21.6
3.92
—
(5.9)
(9.5)
(2.2)
(44.3)
GOODRICKE GROUP LTD.
474
5.6
1.56
—
8.4
5.0
—
(22.7)
THE P K TEA PROD CO LTD
348
64.5
1.82
29.5
2.8
3.2
—
50.0
JAYSHREE TEA & INDUSTRIES
268
—
0.68
21.4
(6.3)
(5.1)
3.0
4.9
UNITED NILGIRI TEA LTD
216
10.7
0.90
—
9.1
10.4
—
43.5
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 5: Where the company sits in its group
Metric
Company
Group median
Rank
Better than
P/E (TTM)
1.2
7.8
2 of 24
96%
P/B
10.8
0.7
27 of 27
0%
ROCE
(907.6)
3.0
26 of 26
0%
ROE
(907.6)
2.3
27 of 27
0%
Debt / Equity
0.0
0.2
1 of 27
81%
EBITDA margin
(1.0)
11.9
17 of 26
36%
Profit growth
(158.4)
18.5
23 of 27
15%
Market cap
6
115
26 of 27
4%
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
The current price and the multiples against the group
a target is a forecast; a multiple is a measurement
Estimate years marked E
More audited years; no estimates
MarketPing publishes no forecasts — your own model lives on the Models page
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
